Sylvie Zanetta

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

Gwénaëlle Gravis, Karim Fizazi, Florence Joly et al. · The Lancet Oncology · 2013 · 727 citations

Androgen-deprivation Therapy, Urology, Genitourinary Cancer +7

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 214 citations

Gortec 2014-01 Tpextreme, Neoadjuvant Therapy, Medicine +11

Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.

Alexandre Santos, Sylvie Zanetta, Thierry Cresteil et al. · PubMed · 2000 · 213 citations

Metabolomic Profiling, Secondary Metabolite, Experimental Pharmacology +24

Are Older French Patients As Willing As Older American Patients to Undertake Chemotherapy?

Martine Extermann, G. Albrand, Hongbin Chen et al. · Journal of Clinical Oncology · 2003 · 179 citations

Visceral Fat Area as a New Independent Predictive Factor of Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Antiangiogenic Agents

Sylvain Ladoire, Franck Bonnetain, Mélanie Gauthier et al. · The Oncologist · 2011 · 170 citations · Full text

Prognostic Biomarkers, Urology, Angiogenesis +14